Your browser doesn't support javascript.
loading
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen, Ezra Y; Johnson, Melissa L; Clifford, Sarah E; Somwar, Romel; Kherani, Jennifer F; Son, Jieun; Bertram, Arrien A; Davare, Monika A; Gladstone, Eric; Ivanova, Elena V; Henry, Dahlia N; Kelley, Elaine M; Lin, Mika; Milan, Marina S D; Nair, Binoj C; Olek, Elizabeth A; Scanlon, Jenna E; Vojnic, Morana; Ebata, Kevin; Hechtman, Jaclyn F; Li, Bob T; Sholl, Lynette M; Taylor, Barry S; Ladanyi, Marc; Jänne, Pasi A; Rothenberg, S Michael; Drilon, Alexander; Oxnard, Geoffrey R.
Afiliação
  • Rosen EY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Johnson ML; Department of Medicine, Sarah Cannon Cancer Center, Nashville, Tennessee.
  • Clifford SE; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kherani JF; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Son J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bertram AA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Davare MA; Oregon Health and Science University, Portland, Oregon.
  • Gladstone E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ivanova EV; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Henry DN; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Kelley EM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lin M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Milan MSD; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Nair BC; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Olek EA; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Scanlon JE; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vojnic M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ebata K; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Hechtman JF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Li BT; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sholl LM; Weill Cornell Medical College, New York, New York.
  • Taylor BS; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Ladanyi M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jänne PA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rothenberg SM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Drilon A; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.
  • Oxnard GR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. drilona@mskcc.org.
Clin Cancer Res ; 27(1): 34-42, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33082208
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Proteínas Proto-Oncogênicas c-met / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Proteínas Proto-Oncogênicas c-met / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article